The primary objective of the study is to prospectively evaluate pregnancy outcomes in women
with multiple sclerosis who were exposed to a Registry-specified Biogen Multiple Sclerosis
product during the eligibility window for that product. The Registry-specified Biogen MS
products being studied are dimethyl fumarate, and Pegylated human interferon beta-1a. The
secondary objective of the study is to prospectively evaluate pregnancy outcomes in women
with MS who were unexposed to disease-modifying therapies (DMTs).